Trial Profile
A phase III study of ALG-1001 (Luminate) for the treatment of non-proliferative diabetic retinopathy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2016
Price :
$35
*
At a glance
- Drugs Risuteganib (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 01 Aug 2016 New trial record